Data Monitoring Committees Are Useful For High-Risk Phase I/II Trials – FDA
This article was originally published in The Gray Sheet
Executive Summary
FDA strongly recommends data monitoring committees for early-phase clinical trials where the investigator is also the sponsor, or where subjects may be placed at unusual risk, a Nov. 16 draft guidance on DMCs states